These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10758016)

  • 1. How to manage metabolic complications of HIV therapy: what to do while we wait for answers.
    Currier JS
    AIDS Read; 2000 Mar; 10(3):162-9; discussion 171-4. PubMed ID: 10758016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities.
    Henry K; Melroe H; Huebesch J; Hermundson J; Simpson J
    Lancet; 1998 Sep; 352(9133):1031-2. PubMed ID: 9759748
    [No Abstract]   [Full Text] [Related]  

  • 3. Intervention for hyperlipidemia associated with protease inhibitors.
    Melroe NH; Kopaczewski J; Henry K; Huebsch J
    J Assoc Nurses AIDS Care; 1999; 10(4):55-69. PubMed ID: 10394560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities.
    Moyle G; Carr A
    HIV Clin Trials; 2002; 3(1):89-98. PubMed ID: 11894812
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors.
    Martínez E; Domingo P; Ribera E; Milinkovic A; Arroyo JA; Conget I; Pérez-Cuevas JB; Casamitjana R; de Lazzari E; Bianchi L; Montserrat E; Roca M; Burgos R; Arnaiz JA; Gatell JM
    Antivir Ther; 2003 Oct; 8(5):403-10. PubMed ID: 14640387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unsolved mystery of fat redistribution.
    STEP Perspect; 1999; 99(1):6-7. PubMed ID: 11367164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes in carbohydrate metabolism in the HIV/AIDS patient].
    Gómez Candela C; de Cos Blanco AI; Mateo R; Castro E; Lorenzo A; Polo R
    Nutr Hosp; 2002; 17(3):147-53. PubMed ID: 12149814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for treating HIV-related lipodystrophy.
    García-Viejo MA; Ruíz M; Martínez E
    Expert Opin Investig Drugs; 2001 Aug; 10(8):1443-56. PubMed ID: 11772261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fat, sugar and drugs on the French Riviera.
    Lands L
    GMHC Treat Issues; 1999 Mar; 13(3):9-11. PubMed ID: 11366205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoprotein c-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy.
    Bonnet E; Ruidavets JB; Tuech J; Ferrières J; Collet X; Fauvel J; Massip P; Perret B
    J Clin Endocrinol Metab; 2001 Jan; 86(1):296-302. PubMed ID: 11232015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Metabolic side effects of antiretroviral therapy].
    van der Valk M; Reiss P
    Ned Tijdschr Geneeskd; 2008 May; 152(22):1260-4. PubMed ID: 18590059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection.
    Silverberg MJ; Leyden W; Hurley L; Go AS; Quesenberry CP; Klein D; Horberg MA
    Ann Intern Med; 2009 Mar; 150(5):301-13. PubMed ID: 19258558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease.
    Vigouroux C; Gharakhanian S; Salhi Y; Nguyên TH; Adda N; Rozenbaum W; Capeau J
    Diabetes Metab; 1999 Nov; 25(5):383-92. PubMed ID: 10592860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the trail of fugitive fat: the chase turns to NRTIs.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1999 Oct; 5(10):24-43. PubMed ID: 11366871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.
    Brinkman K; Smeitink JA; Romijn JA; Reiss P
    Lancet; 1999 Sep; 354(9184):1112-5. PubMed ID: 10509516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HAART-associated body habitus and metabolic changes, Part 1.
    Liss M; Boyle BA
    AIDS Read; 2000 Nov; 10(11):622, 629-31. PubMed ID: 11186180
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients.
    Chêne G; Angelini E; Cotte L; Lang JM; Morlat P; Rancinan C; May T; Journot V; Raffi F; Jarrousse B; Grappin M; Lepeu G; Molina JM
    Clin Infect Dis; 2002 Mar; 34(5):649-57. PubMed ID: 11810598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients.
    Chen D; Misra A; Garg A
    J Clin Endocrinol Metab; 2002 Nov; 87(11):4845-56. PubMed ID: 12414837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic complications of HIV and AIDs.
    Briggs JM; Drabek CA
    Orthop Nurs; 2001; 20(4):41-50. PubMed ID: 12025672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing HIV lipoatrophy.
    Moyle G; Sutinen J
    Lancet; 2004 Feb; 363(9407):412-4. PubMed ID: 14962517
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.